67-letni mężczyzna z przewlekłą chorobą niedokrwienną serca i nasiloną niewydolnością serca Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2011
##plugins.themes.bootstrap3.article.main##
Abstrakt
Brak
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2011). 67-letni mężczyzna z przewlekłą chorobą niedokrwienną serca i nasiloną niewydolnością serca . Medycyna Faktów , 4(4(13), 66-69. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2506
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. McMurray J., Pfeffer M.A.: New Therapeutic Options in Congestive Heart Failure: Part I. Circulation 2002; 105: 2099-2104.
2. Vitale C., Wajngaten M., Sposato B. et al.: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. 2004; 25: 1814-1821.
3. Malmberg K., Norhammar A., Wedel H. et al.: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632.
4. Szwed H., Sadowski Z., Pachocki R. et al.: Anti-Ischaemic Efficacy and Tolerability of Trimetazidine in Elderly Patients with Angina Pectoris A Sub- Study from TRIMPOL-1 (Trimetazidine in Poland). Clin. Drug Invest. 2000; 19: 1-8.
5. Morgan E.E., Young M.E., McElfresh T.A. et al.: Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Fundam. Clin. Pharmacol. 2006; 20(5): 503-505.
6. Fragasso G., Palloshi A., Puccetti P. et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 2006; 48: 992-998.
7. Gunes Y., Guntekin U., Tuncer M. et al.: Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009; 24: 277-282.
8. Gunes Y., Tuncer M., Guntekin U. et al.: The effects of trimetazidine on p-wave duration and dispersion in heart failure patients. Pacing Clin. Electrophysiol. 2009; 32: 239-244.
9. Gao D., Ning N., Niu X., Hao G., Meng Z.: Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97(4): 278-286.
10. Tallarico D., Rizzo V., Di Maio F. et al.: Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 2003; 54(2): 219-227.
2. Vitale C., Wajngaten M., Sposato B. et al.: Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur. Heart J. 2004; 25: 1814-1821.
3. Malmberg K., Norhammar A., Wedel H. et al.: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632.
4. Szwed H., Sadowski Z., Pachocki R. et al.: Anti-Ischaemic Efficacy and Tolerability of Trimetazidine in Elderly Patients with Angina Pectoris A Sub- Study from TRIMPOL-1 (Trimetazidine in Poland). Clin. Drug Invest. 2000; 19: 1-8.
5. Morgan E.E., Young M.E., McElfresh T.A. et al.: Chronic treatment with trimetazidine reduces the upregulation of atrial natriuretic peptide in heart failure. Fundam. Clin. Pharmacol. 2006; 20(5): 503-505.
6. Fragasso G., Palloshi A., Puccetti P. et al.: A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J. Am. Coll. Cardiol. 2006; 48: 992-998.
7. Gunes Y., Guntekin U., Tuncer M. et al.: Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study. Heart Vessels 2009; 24: 277-282.
8. Gunes Y., Tuncer M., Guntekin U. et al.: The effects of trimetazidine on p-wave duration and dispersion in heart failure patients. Pacing Clin. Electrophysiol. 2009; 32: 239-244.
9. Gao D., Ning N., Niu X., Hao G., Meng Z.: Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011; 97(4): 278-286.
10. Tallarico D., Rizzo V., Di Maio F. et al.: Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology 2003; 54(2): 219-227.